Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122492) titled 'A Prospective, Multicenter, Open-Label Clinical Study of Photodynamic Therapy Combined with Serplulimab, Chemotherapy (XELOX), and Bevacizumab for the Treatment of MSS/pMMR Locally Advanced Colorectal Cancer' on April 14.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shanghai General Hospital
Condition:
MSS/pMMR type colorectal cancer
Intervention:
Group A:Cycle 1: PDT + serplulimab + bevacizumab
Subsequent cycles: serplulimab + XELOX + bevacizumab
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-04-15
Target Sample Size: Group A:40;Group B:40; ...